Welcome to Markets Desk, here's what's moving the needle this hour.
Philip Morris International is trimming its outlook for both the second quarter and full-year two thousand twenty six, citing currency headwinds and a non-cash impairment charge tied to its Rothmans, Benson and Hedges unit in Canada. That kind of guidance cut signals real pressure on international earnings when the dollar stays strong and legacy tobacco assets start losing book value.
Shifting to Washington, President Trump has appointed Bill Pulte, currently director of the Federal Housing Finance Agency, as acting director of national intelligence. The move raises eyebrows given the distance between housing finance and the intelligence community, though the White House is framing Pulte's tenure overseeing sensitive institutional matters as relevant preparation for the role.
And in biotech, Firefly Neuroscience says it has identified a novel electrophysiological biomarker for post-traumatic stress disorder using its FDA-cleared Evoke System. For a small-cap name like Firefly, a credible biomarker discovery in a condition as underserved as PTSD can be a genuine inflection point, drawing attention from both clinical partners and investors watching the neuroscience space closely.
That's the tape. Markets Desk, signing off the floor.
